Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.59 |
| ▸ | BRD4 | O60885 | 5/20 | 0.59 |
| ▸ | JAK1 | P23458 | 5/20 | 0.59 |
| ▸ | JAK3 | P52333 | 5/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | TYK2 | P29597 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 11/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | TEK | Q02763 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.51 |
| ▸ | YES1 | P07947 | 2/20 | 0.51 |
| ▸ | LYN | P07948 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995311 | 0.91 | SRC (0.54) | JAK2BRD4JAK1JAK3HDAC1 | |
| SCHEMBL5997421 | 0.84 | SRC (0.57) | JAK2BRD4JAK1JAK3HDAC1 | |
| SCHEMBL12190215 | 0.82 | BRD4 (0.57) | JAK2BRD4JAK1JAK3HDAC1 | |
| SCHEMBL2496549 | 0.81 | LCK (0.56) | JAK2BRD4JAK1JAK3HDAC1 | |
| SCHEMBL5997067 | 0.81 | SRC (0.55) | SRCPDGFRBABL1YES1EPHB4 | |
| SCHEMBL2493240 | 0.80 | LCK (0.53) | JAK2BRD4JAK1JAK3HDAC1 | |
| SCHEMBL5998263 | 0.80 | LCK (0.55) | SRCKDRLCKEGFRYES1 | |
| SCHEMBL31745353 | 0.80 | JAK1 (0.59) | JAK2BRD4JAK1JAK3HDAC1 | |
| SCHEMBL7862109 | 0.79 | KDR (0.63) | KDRBRAF | |
| SCHEMBL2493709 | 0.79 | LCK (0.70) | JAK2JAK3SRCKDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | JAK2 122/4885BRD4 1338/4885JAK1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.